Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).

被引：0
|
作者：
Leong, Sally
Ali, Sana
Zengin, Zeynep Busra
Meza, Luis A.
Dizman, Nazli
Ebrahimi, Hedyeh
Govindarajan, Ameish
Castro, Daniela V.
Li, Xiaochen
Kim, Tane
Melamed, Sam
Pal, Sumanta Monty
Chehrazi-Raffle, Alex
机构：
[1] Harbor UCLA Med Ctr, Torrance, CA USA
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Lundquist Res Inst, Torrance, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
613
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Tucker, Matthew D.
    Brown, Landon Carter
    Kao, Chester
    Hirshman, Nathan
    Kinsey, Emily Noelle
    Chen, Yu-Wei
    Ancell, Kristin Kathleen
    Beckermann, Katy
    Davis, Nancy B.
    McAlister, Renee
    Schaffer, Kerry
    Armstrong, Andrew J.
    Harrison, Michael Roger
    George, Daniel J.
    Rathmell, Wendy Kimryn
    Rini, Brian I.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Clinical characteristics of responders to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma.
    Shephard, Michael Paul
    Glover, Maura
    Balmes, Gener
    Cain, Suzanne
    Vardeleon, Anna
    Mouton, Rosalind
    Posada, Liberty
    Simien, Rinata
    Hwu, Patrick
    Davies, Michael
    Yee, Cassian
    Wong, Michael
    Tawbi, Hussein
    Woodman, Scott
    Amaria, Rodabe
    Diab, Adi
    Glitza, Isabella
    Hwu, Wen-Jen
    Patel, Sapna
    CANCER RESEARCH, 2020, 80 (19) : 38 - 38
  • [23] A phase 2 study of nivolumab (NIVO) alone or plus ipilimumab (IPI) for patients with locally advanced unresectable (IaBCC) or metastatic basal cell carcinoma (mBCC).
    Stein, Julie E.
    Brothers, Patricia
    Applebaum, Katie
    Gaskin, Angela
    Wang, Hao
    Taube, Janis M.
    Lipson, Evan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
    Callahan, Margaret K.
    Kania, Brooke Elizabeth
    Iyer, Gopa
    Clement, Jessica Mary
    Funt, Samuel
    McCoy, Asia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [25] Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC).
    Alhalabi, Omar
    Wilson, Nathaniel
    Ajufo, Helen
    Lehner, Michael
    Hasanov, Elshad
    Campbell, Matthew T.
    Shah, Amishi Yogesh
    Wang, Jennifer
    Jonasch, Eric
    Araujo, John C.
    Wang, Jianbo
    Gao, Jianjun
    Goswami, Sangeeta
    Msaouel, Pavlos
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] Peripheral immunomodulatory changes in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab
    Almeida, Lorena
    Maia, Manuel
    Won, Haejung
    Moreira, Dayson
    Bergerot, Paulo
    Kortylewski, Marcin
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [27] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M.
    Rini, B. I.
    McDermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M.
    Sharma, P.
    Kollmannsberger, C. K.
    Heng, D.
    Shen, Y.
    Kurland, J.
    Spratlin, J.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2014, 25
  • [28] Safety and efficacy of nivolumab plus ipilimumab (NIVO plus IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.
    Emamekhoo, Hamid
    Olsen, Mark
    Carthon, Bradley Curtis
    Drakaki, Alexandra
    Percent, Ivor John
    Molina, Ana M.
    Cho, Daniel C.
    Bendell, Johanna C.
    Gordan, Lucio N.
    Kalebasty, Arash Rezazadeh
    George, Daniel J.
    Hutson, Thomas E.
    Lee, Richard J.
    Young, Tina C.
    Johansen, Jennifer
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Razak, Albiruni R. A.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345